Company profile
CannaPharmaRX, Inc.
OTC: CPMD · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Calgary, ABCIK 0001081938Reports USD
#844 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
38DFH 28DQ 48GM —SS 54
v0.1 · 55/100 weight · provisional
↑ listing tenure, revenue growth (YoY) · ↓ balance-sheet leverage, filing timeliness
Methodology →Revenue TTM
$1.7M
Rev growth YoY (TTM)
+24.8%
Net income (FY)
-$11.1M
Employees
26
as of 2026-08-25
Market cap
$1.3M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M$1.4M2025
Net income-$11.1M-$11.1M2025
Operating income-$3.3M-$3.3M2025
Total assets$7.0M$7.0M2025
Liabilities$37.2M$37.2M2025
Equity-$30.2M-$30.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CannaPharmaRX, Inc.’s revenue?
CannaPharmaRX, Inc. booked $1.4M in FY2025 revenue, growing 66% year over year — faster than most Healthcare companies we track, at a -817.2% net margin.
Peers · Healthcare
Vasamed, Inc.——Northwest Biotherapeutics, Inc.40DAffymax, Inc.——OneMedNet Corporation26DPanbela Therapeutics, Inc.——Electromedical Technologies, Inc.——Key facts
CEOConstantine Nkafu
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCalgary, AB
ExchangeOTC: CPMD
Employees26
IPO date1999-10-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.